---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-129378"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:35:53.714041+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics selects lead oral amylin agonist ACCG-2671 for obesity; Phase 1 start by end-2025

## Summary
- ACCG-2671 is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) designed for once-daily oral dosing.
- Preclinical data show cagrilintide-like efficacy with potent target engagement and favorable safety profile.
- Phase 1 clinical development expected to begin by year end 2025.
- Company believes ACCG-2671 could serve as backbone therapy for fixed-dose oral combinations with GLP-1 candidate GSBR-1290.
- Structure is developing a series of amylin-based candidates using its GPCR structure-based drug discovery platform.

## SEC filing metadata
- accession: 0001104659-24-129378
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465924129378/0001104659-24-129378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465924129378/tm2431274d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-129378
- JSON: https://secwatch.observer/filing/0001104659-24-129378.json
- Plain text: https://secwatch.observer/filing/0001104659-24-129378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.